Published Date: 17 Mar 2023
NEW DELHI: The National Medical Commission (NMC) has requested all medical schools to schedule examination appointments for Broad...
Read Full NewsTake 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.
A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.
A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.
The single-arm CLAD-MAPET study is evaluating whether cladribine tablets reduce microglial activation, captured by [F-18]PBR06-PET, in patients with MS experiencing progression without relapse or MRI activity on anti-CD20 therapy.
Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD
The HCPFive: Top News for Healthcare Providers from the Week of 02/01
HCPLive 5 Stories in Under 5: Week of 02/01
1.
Limited Benefit from New Drugs; Significant Increase in Drug Prices; AI Boost for Mammo Results.
2.
Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.
3.
Prior authorizations draining time, energy from many cancer patients
4.
Team finds broken 'brake' on cancer mutation machine.
5.
Ketamine plus psychotherapy for "excellent" PTSD
1.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
2.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
3.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
4.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
5.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
4.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation